BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 713.07M | 579.96M | 502.08M | 353.78M | 235.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 713.07M | 579.96M | 502.08M | 353.78M | 235.81M |
| Cost of Revenue | 39.66M | 28.26M | 20.96M | 14.94M | 8.97M |
| Gross Profit | 673.41M | 551.70M | 481.11M | 338.84M | 226.84M |
| SG&A Expenses | 645.86M | 588.76M | 531.23M | 467.92M | 399.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.19B | 1.08B | 1.00B | 948.75M | 881.55M |
| Operating Income | -477.82M | -504.22M | -502.06M | -594.97M | -645.74M |
| Income Before Tax | -703.68M | -729.45M | -732.50M | -803.98M | -781.76M |
| Income Tax Expenses | -1.67M | 435.00K | 435.00K | 1.71M | 3.25M |
| Earnings from Continuing Operations | -702.02 | -729.89 | -732.94 | -805.69 | -785.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.15M | 8.33M | 8.01M | 8.57M | 8.59M |
| Net Income | -691.87M | -721.55M | -724.93M | -797.12M | -776.42M |
| EBIT | -477.82M | -504.22M | -502.06M | -594.97M | -645.74M |
| EBITDA | -472.75M | -498.88M | -496.63M | -589.60M | -640.23M |
| EPS Basic | -3.57 | -3.75 | -3.78 | -4.19 | -4.09 |
| Normalized Basic EPS | -2.15 | -2.25 | -2.20 | -2.47 | -2.59 |
| EPS Diluted | -3.57 | -3.75 | -3.78 | -4.19 | -4.09 |
| Normalized Diluted EPS | -2.15 | -2.25 | -2.20 | -2.47 | -2.59 |
| Average Basic Shares Outstanding | 775.98M | 770.71M | 766.07M | 761.95M | 758.61M |
| Average Diluted Shares Outstanding | 775.98M | 770.71M | 766.07M | 761.95M | 758.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |